Suppression of multiple myeloma by mitochondrial targeting

Suppression of multiple myeloma by mitochondrial targeting

Abstract Treatment of multiple myeloma (MM) aims at inducing cell apoptosis by surpassing the limited capacity of MM cells to cope with oxidative stress. MM cell survival may further be suppressed by limiting cellular cholesterol. Long-chain fatty acid analogs of the MEDICA series promote mitochondr...

Full description

Bibliographic Details
Main Authors:	Yana Aisen, Moshe E. Gatt, Rachel Hertz, Elia Smeir, Jacob Bar-Tana
Format:	Article
Language:	English
Published:	Nature Portfolio 2021-03-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-83829-2

Similar Items

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
by: Ortal Harush, et al.
Published: (2022-03-01)

Do older patients truly benefit from advances in myeloma care?
by: Moshe E. Gatt, et al.
Published: (2022-10-01)

Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma
by: Rikio Suzuki, et al.
Published: (2022-11-01)

Amyloidogenic light chains impair plasma cell survival
by: Marjorie Pick, et al.
Published: (2023-06-01)

Targeting the Resistance in Multiple Myeloma
by: Micaela Freitas, et al.
Published: (2019-04-01)

Osteoblast suppression in multiple myeloma bone disease
by: Juraj Adamik, et al.
Published: (2018-11-01)

Targeted therapy of multiple myeloma
by: Shan Zhou, et al.
Published: (2021-10-01)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
by: Efrat Markus, et al.
Published: (2020-05-01)

Targeting the ribosome to treat multiple myeloma
by: Kylee H. Maclachlan, et al.
Published: (2024-03-01)

NOVEL TARGETS AND THERAPIES IN MULTIPLE MYELOMA
by: Meral Uluköylü Mengüç
Published: (2024-12-01)

Bone-targeted agents in multiple myeloma
by: Hiroko Nishida
Published: (2018-03-01)

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
by: Nadeem O, et al.
Published: (2020-10-01)

PIKing the next therapeutic target in multiple myeloma
by: Jessica L. Caro, et al.
Published: (2020-06-01)

Selinexor: Targeting a novel pathway in multiple myeloma
by: Clifton C. Mo, et al.
Published: (2023-08-01)

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma
by: Tianyi Ye, et al.
Published: (2024-05-01)

Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p
by: Haiyan Liu, et al.
Published: (2019-10-01)

Transcriptional regulation of human microsomal triglyceride transfer protein by hepatocyte nuclear factor-4α
by: Vered Sheena, et al.
Published: (2005-02-01)

Immunogenic Targets for Specific Immunotherapy in Multiple Myeloma
by: Lu Zhang, et al.
Published: (2012-01-01)

Bispecific antibody targets and therapies in multiple myeloma
by: Matthew Rees, et al.
Published: (2024-10-01)

Multiple myeloma: signaling pathways and targeted therapy
by: Qizhong Lu, et al.
Published: (2024-07-01)

Polycomb target genes are silenced in multiple myeloma.
by: Antonia Kalushkova, et al.
Published: (2010-07-01)

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.
by: Fowler, J, et al.
Published: (2011)

Icaritin‐elevated circ_0000190 suppresses the malignant progression of multiple myeloma by targeting miR‐301a
by: Yu‐Hui Zhu, et al.
Published: (2022-05-01)

Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy
by: Remya Nair, et al.
Published: (2022-09-01)

The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma
by: Murat Sarı, et al.
Published: (2017-05-01)

Epigenetic‐Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease
by: Juraj Adamik, et al.
Published: (2019-03-01)

LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma
by: Lixin Gong, et al.
Published: (2024-05-01)

Bortezomib in the management of multiple myeloma
by: Jacob P Laubach, et al.
Published: (2009-09-01)

Identification of PIKfyve kinase as a target in multiple myeloma
by: Cecilia Bonolo de Campos, et al.
Published: (2020-06-01)

Targeting GPRC5D for multiple myeloma therapy
by: Dian Zhou, et al.
Published: (2024-09-01)

An overview of pim kinase as a target in multiple myeloma
by: Zhaoyun Liu, et al.
Published: (2023-05-01)

Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
by: Valentina Urzì Brancati, et al.
Published: (2023-04-01)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar D, et al.
Published: (2015-01-01)

PF-4708671 activates AMPK independently of p70S6K1 inhibition.
by: Gilad W Vainer, et al.
Published: (2014-01-01)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
by: Vanessa Innao, et al.
Published: (2021-02-01)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
by: Fatih M. Uckun, et al.
Published: (2021-11-01)

Suppression of adipose lipolysis by long-chain fatty acid analogs
by: Bella Kalderon, et al.
Published: (2012-05-01)

Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity
by: Roberta Torcasio, et al.
Published: (2024-02-01)

Insulin Resistance, Secretion and Clearance –Taming the Three Effector Encounter of Type 2 Diabetes
by: Jacob Bar-Tana
Published: (2021-09-01)